Gastrointestinal Cancer

Harry H. Yoon, MD discussed the promise of immunotherapy and emphasized the importance of mismatch repair deficiency testing in gastric/GEJ Cancer.

In its fight against pancreatic cancer, the Pancreatic Cancer Action Network aims to improve current survival and double survival by 2020.

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

There is an urgent need for new approaches, particularly since pancreatic cancer is expected to become the second leading cause of cancer-related mortality by 2030.

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

Optimizing frontline therapy for patients with pancreatic cancer is an ongoing focal point in the field.

The FDA has accepted a supplemental new drug application for lenvatinib as a frontline systemic treatment for patients with advanced hepatocellular carcinoma.

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Steven R. Alberts, MD, discusses current advancements being made for patients with advanced liver cancer.

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.

Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).

BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).